A retrospective cohort study5 revealed that adjuvant EGFR-TKIs post-surgical resection provided a sustained and clinically significant 5-year Disease-Free Survival (DFS) benefit in stage I NSCLC patients, both in stage IA (EGFR-TKIs vs. observation = 100.0% vs. 84.5%; P = 0.007) and stage IB (EGFR-TKIs vs. observation = 98.8% vs. 75.3%; P = 0.008). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.